New sedative shows promise for ventilated ICU patients

NCT ID NCT06124404

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called remimazolam besylate for sedating patients in the intensive care unit who are on breathing machines. The trial involved 36 adults and compared three different doses to see how well the drug kept patients lightly sedated without needing extra medication. The goal is to find a safe and effective sedation option for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

remimazolam besylate

What this could lead to

If successful, this could provide a safer, more controllable sedation option for ICU patients on ventilators.

What could go wrong

This is a small, early-phase trial with only 36 participants. The results may not apply to all ICU patients, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MECHANICALLY VENTILATED PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wuhan Union Hospital

    Wuhan, Hubei, 430022, China